Moderna (MRNA) closed at $63.94 in the latest trading session, marking a -0.31% move from the prior day. This change lagged the S&P 500's 0.25% gain on the day. At the same time, the Dow added 0.2%, ...

RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...

The H5N1 virus, known for its 50% human case fatality rate, has persisted globally for over two decades, causing thousands of ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...

Moderna’s recent stock drop reflects investor concerns over the company’s revised financial outlook and strategic shifts. Despite its pioneering role in mRNA technology and promising future prospects, ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Moderna (MRNA – Research Report), with a price ...

Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.

The study investigates COVID-19 vaccine-related myocarditis in adolescents, revealing clinical characteristics and risks of ...